UF Innovate Ventures has contributed to a series B round for StrideBio, partially based on research into gene therapies at University of Florida.

StrideBio, a US-based gene therapy developer exploiting research undertaken at University of Florida (UF) and University of North Carolina at Chapel Hill, closed an $81.5m series B round yesterday backed by the former institution’s venture fund UF Innovate Ventures.
Pharmaceutical firm Novo and Northpond Ventures co-led the round, which also attracted biopharmaceutical companies Sarepta Therapeutics and UCB as well as pharmaceutical firm Takeda and life science real estate developer Alexandria Real Estate Equities.
Pontifax, Octagon Capital, CaaS Capital…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in